A Phase 2b Study of DIO-902 or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo for Type 2 Diabetes
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Sherwyn Schwartz, MD
Diabetes & Glandular Disease Research Associates
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
24 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Flinders Medical Centre
Adelaide, South Australia, Australia
- Lyell Mcewin Hospital
North Western Adelaide, South Australia, Australia
- Ecru
Box Hill, Melbourne, Victoria, Australia
- School of Medicine and Pharmacology
Fremantle, Western Australia, Australia
- Keough Institute
Nedands, Western Australia, Australia
- Endocrinology Research Unit
Herston Road, Australia
- Endocrinology Department
St Leonards, Australia
- Royal Melbourn Hospital
Victoria, Australia
- Middlemore Hospital
Otahuhu, Auckland, New Zealand
- Lipid and Diabetes Research
Christchurch, New Zealand
- Waikaito Hospital
Hamilton, New Zealand
- Diabetes Centre
Wellington, New Zealand
- Dr. Terence Hart
Muscle Shoals, Alabama, United States
- Genova Research
Tucson, Arizona, United States
- Research Solutions
Jonesboro, Arkansas, United States
- Arkansas Primary Care Clinic
Little Rock, Arkansas, United States
- Advanced Medical Research
Lakewood, California, United States
- Mills-Peninsula Helath Services
San Mateo, California, United States
- Diabetes Research Goup University of Hawaii at Manoa
Honolulu, Hawaii, United States
- Creighton Diabetes Center
Omaha, Nebraska, United States
- Ahs Oklahoma Physician Group
Tulsa, Oklahoma, United States
- Covance Clinical Research Unit - Dr. Andrew Ahmann
Portland, Oregon, United States
- Covance Cru
Austin, Texas, United States
- Diabetes Glandular and Disease Research Associates
San Antonio, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2007
- Primary completion
- 31 Mar 2008
- Completion
- 31 Dec 2008
- Last update posted
- 13 Nov 2008
- Registered enrollment
- 200
- Registry id
- NCT00494663
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.